Migraine Treatment in ED

• Status: Withdrawn
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Randomized pilot feasibility study evaluating the impact of introducing behavioral treatment for migraine in the Emergency Department (ED) and prescribing migraine preventive medications in the ED. The study will examine the effect of these treatments, both individually and in combination, on pain severity and headache-related disability. This study is designed to examine the feasibility of comparing four interventions for ED patients presenting with migraine. Group 1: Starting topiramate; Group 2: Doing a brief behavioral intervention; Group 3: Treating with combination therapy of topiramate and behavioral intervention; and Group 4: Standard of Care.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Naproxen; Sumatriptan; Topiramate

Criteria

Inclusion Criteria:

• age 18 years to 65 years of age

• primary diagnosis of migraine based on the International Classification of headache disorders 3 beta criteria

• having a migraine 3 or more days/month.

Exclusion Criteria:

• Cognitive Behavioral Therapy (CBT), biofeedback or other relaxation therapy in the past year

• being on medication used for migraine prevention (topiramate, propranolol, valproic acid, amitriptyline/nortriptyline/imipramine/desipramine, botulinum toxin, a SNRI, angiotensin-converting enzyme inhibitors (ACE-I) or ARB)

• cognitive deficit or other physical problem with the potential to interfere with behavioral therapy

• substance or alcohol abuse as determined by self-report or prior documentation in the medical record.